Rayhan A Lal1,2,3, Marina Basina4,3, David M Maahs2,3, Korey Hood2,3, Bruce Buckingham2,3, Darrell M Wilson2,3. 1. Division of Endocrinology, Department of Medicine, Stanford University School of Medicine, Stanford, CA inforay@stanford.edu. 2. Division of Endocrinology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA. 3. Stanford Diabetes Research Center, Stanford, CA. 4. Division of Endocrinology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
Abstract
OBJECTIVE: In September 2016, the U.S. Food and Drug Administration approved the Medtronic 670G "hybrid" closed-loop system. In Auto Mode, this system automatically controls basal insulin delivery based on continuous glucose monitoring data but requires users to enter carbohydrates and blood glucose for boluses. To track real-world experience with this first commercial closed-loop device, we prospectively followed pediatric and adult patients starting the 670G system. RESEARCH DESIGN AND METHODS: This was a 1-year prospective observational study of patients with type 1 diabetes starting the 670G system between May 2017 and May 2018 in clinic. RESULTS: Of the total of 84 patients who received 670G and consented, 5 never returned for follow-up, with 79 (aged 9-61 years) providing data at 1 week and 3, 6, 9, and/or 12 months after Auto Mode initiation. For the 86% (68 out of 79) with 1-week data, 99% (67 out of 68) successfully started. By 3 months, at least 28% (22 out of 79) had stopped using Auto Mode; at 6 months, 34% (27 out of 79); at 9 months, 35% (28 out of 79); and by 12 months, 33% (26 out of 79). The primary reason for continuing Auto Mode was desire for increased time in range. Reasons for discontinuation included sensor issues in 62% (16 out of 26), problems obtaining supplies in 12% (3 out of 26), hypoglycemia fear in 12% (3 out of 26), multiple daily injection preference in 8% (2 out of 26), and sports in 8% (2 out of 26). At all visits, there was a significant correlation between hemoglobin A1c (HbA1c) and Auto Mode utilization. CONCLUSIONS: While Auto Mode utilization correlates with improved glycemic control, a focus on usability and human factors is necessary to ensure use of Auto Mode. Alarms and sensor calibration are a major patient concern, which future technology should alleviate.
OBJECTIVE: In September 2016, the U.S. Food and Drug Administration approved the Medtronic 670G "hybrid" closed-loop system. In Auto Mode, this system automatically controls basal insulin delivery based on continuous glucose monitoring data but requires users to enter carbohydrates and blood glucose for boluses. To track real-world experience with this first commercial closed-loop device, we prospectively followed pediatric and adult patients starting the 670G system. RESEARCH DESIGN AND METHODS: This was a 1-year prospective observational study of patients with type 1 diabetes starting the 670G system between May 2017 and May 2018 in clinic. RESULTS: Of the total of 84 patients who received 670G and consented, 5 never returned for follow-up, with 79 (aged 9-61 years) providing data at 1 week and 3, 6, 9, and/or 12 months after Auto Mode initiation. For the 86% (68 out of 79) with 1-week data, 99% (67 out of 68) successfully started. By 3 months, at least 28% (22 out of 79) had stopped using Auto Mode; at 6 months, 34% (27 out of 79); at 9 months, 35% (28 out of 79); and by 12 months, 33% (26 out of 79). The primary reason for continuing Auto Mode was desire for increased time in range. Reasons for discontinuation included sensor issues in 62% (16 out of 26), problems obtaining supplies in 12% (3 out of 26), hypoglycemia fear in 12% (3 out of 26), multiple daily injection preference in 8% (2 out of 26), and sports in 8% (2 out of 26). At all visits, there was a significant correlation between hemoglobin A1c (HbA1c) and Auto Mode utilization. CONCLUSIONS: While Auto Mode utilization correlates with improved glycemic control, a focus on usability and human factors is necessary to ensure use of Auto Mode. Alarms and sensor calibration are a major patient concern, which future technology should alleviate.
Authors: Jennifer L Sherr; Martin Tauschmann; Tadej Battelino; Martin de Bock; Gregory Forlenza; Rossana Roman; Korey K Hood; David M Maahs Journal: Pediatr Diabetes Date: 2018-10 Impact factor: 4.866
Authors: Richard M Bergenstal; Satish Garg; Stuart A Weinzimer; Bruce A Buckingham; Bruce W Bode; William V Tamborlane; Francine R Kaufman Journal: JAMA Date: 2016-10-04 Impact factor: 56.272
Authors: Gregory P Forlenza; Laurel H Messer; Cari Berget; R Paul Wadwa; Kimberly A Driscoll Journal: Curr Diab Rep Date: 2018-09-26 Impact factor: 4.810
Authors: Mary B Abraham; Jennifer A Nicholas; Grant J Smith; Janice M Fairchild; Bruce R King; Geoffrey R Ambler; Fergus J Cameron; Elizabeth A Davis; Timothy W Jones Journal: Diabetes Care Date: 2017-11-30 Impact factor: 19.112
Authors: Michael P Stone; Pratik Agrawal; Xiaoxiao Chen; Margaret Liu; John Shin; Toni L Cordero; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2018-08-30 Impact factor: 6.118
Authors: M B Abraham; J A Nicholas; T T Ly; H C Roby; N Paramalingam; J Fairchild; B R King; G R Ambler; F Cameron; E A Davis; T W Jones Journal: BMJ Open Date: 2016-04-15 Impact factor: 2.692
Authors: Satish K Garg; Stuart A Weinzimer; William V Tamborlane; Bruce A Buckingham; Bruce W Bode; Timothy S Bailey; Ronald L Brazg; Jacob Ilany; Robert H Slover; Stacey M Anderson; Richard M Bergenstal; Benyamin Grosman; Anirban Roy; Toni L Cordero; John Shin; Scott W Lee; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2017-01-30 Impact factor: 6.118
Authors: Martin Tauschmann; Hood Thabit; Lia Bally; Janet M Allen; Sara Hartnell; Malgorzata E Wilinska; Yue Ruan; Judy Sibayan; Craig Kollman; Peiyao Cheng; Roy W Beck; Carlo L Acerini; Mark L Evans; David B Dunger; Daniela Elleri; Fiona Campbell; Richard M Bergenstal; Amy Criego; Viral N Shah; Lalantha Leelarathna; Roman Hovorka Journal: Lancet Date: 2018-10-03 Impact factor: 202.731
Authors: Alex Zhong; Pratik Choudhary; Chantal McMahon; Pratik Agrawal; John B Welsh; Toni L Cordero; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2016-09-27 Impact factor: 6.118
Authors: Cari Berget; Laurel H Messer; Tim Vigers; Brigitte I Frohnert; Laura Pyle; R Paul Wadwa; Kimberly A Driscoll; Gregory P Forlenza Journal: Pediatr Diabetes Date: 2020-01-07 Impact factor: 4.866
Authors: Laurel H Messer; Cari Berget; Tim Vigers; Laura Pyle; Cristy Geno; R Paul Wadwa; Kimberly A Driscoll; Gregory P Forlenza Journal: Pediatr Diabetes Date: 2020-01-03 Impact factor: 4.866
Authors: Marc D Breton; Lauren G Kanapka; Roy W Beck; Laya Ekhlaspour; Gregory P Forlenza; Eda Cengiz; Melissa Schoelwer; Katrina J Ruedy; Emily Jost; Lori Carria; Emma Emory; Liana J Hsu; Mary Oliveri; Craig C Kollman; Betsy B Dokken; Stuart A Weinzimer; Mark D DeBoer; Bruce A Buckingham; Daniel Cherñavvsky; R Paul Wadwa Journal: N Engl J Med Date: 2020-08-27 Impact factor: 91.245
Authors: Grenye O'Malley; Laurel H Messer; Carol J Levy; Jordan E Pinsker; Gregory P Forlenza; Elvira Isganaitis; Yogish C Kudva; Laya Ekhlaspour; Dan Raghinaru; John Lum; Sue A Brown Journal: Diabetes Technol Ther Date: 2021-04 Impact factor: 6.118
Authors: Persis V Commissariat; Lindsay C Roethke; Jennifer L Finnegan; Zijing Guo; Lisa K Volkening; Deborah A Butler; Eyal Dassau; Stuart A Weinzimer; Lori M Laffel Journal: Pediatr Diabetes Date: 2021-08-09 Impact factor: 4.866